CSBR vs. VECT, SANA, RLAY, TSHA, AUTL, DNA, MGTX, OPT, VALN, and CGEM
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include VectivBio (VECT), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Taysha Gene Therapies (TSHA), Autolus Therapeutics (AUTL), Ginkgo Bioworks (DNA), MeiraGTx (MGTX), Opthea (OPT), Valneva (VALN), and Cullinan Therapeutics (CGEM). These companies are all part of the "medical" sector.
Champions Oncology vs. Its Competitors
Champions Oncology (NASDAQ:CSBR) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
Champions Oncology has a net margin of 10.97% compared to VectivBio's net margin of 0.00%. Champions Oncology's return on equity of 656.65% beat VectivBio's return on equity.
Champions Oncology currently has a consensus target price of $12.00, suggesting a potential upside of 55.84%. Given Champions Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Champions Oncology is more favorable than VectivBio.
In the previous week, Champions Oncology had 1 more articles in the media than VectivBio. MarketBeat recorded 1 mentions for Champions Oncology and 0 mentions for VectivBio. Champions Oncology's average media sentiment score of 1.04 beat VectivBio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.
Champions Oncology received 142 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 60.56% of users gave Champions Oncology an outperform vote while only 43.48% of users gave VectivBio an outperform vote.
41.3% of Champions Oncology shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Champions Oncology has higher revenue and earnings than VectivBio.
Summary
Champions Oncology beats VectivBio on 14 of the 14 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CSBR) was last updated on 6/24/2025 by MarketBeat.com Staff
